This book deals with parallel trade of pharmaceuticals from a Law & Economics perspective. Traditionally, restrictions to parallel trade were regarded negatively because they ran against the rules of the EU internal market. However, in recent judgments (Bayer, Glaxo and Syfait), EU Courts questioned some of the legal principles underpinning the EU policy on parallel trade in the field of pharmaceuticals. This revirement suggested that there might be scope for improvement of such policy. However, how and to what extent this change should be performed remained partially unclear. Through the analysis of the impact that parallel trade of pharmaceuticals has on consumer welfare, both in a static and in a dynamic sense, this work examines whether the current legal approach to parallel trade of pharmaceuticals reflects the findings of economic theory, whether it should change, and, if so, on what basis this adjustment should take place. The analysis does not only provide a policy assessment, but also wishes to offer some insights on one of the issues debated within the process of modernization of EU competition law: how judges should integrate economic reasoning in the antitrust assessment of corporate practices. This book is particularly useful both for practitioners and legal scholars who want to deepen their understanding of the EU pharmaceutical market and of the most recent EU judicial developments in that field, as well as of their implications for EU competition law in a ‘modernized’ context.
‘[..] very high academic research’
in Bulletin Quotidien Europe, 15 June 2011
‘[…] a thorough, well-researched, and well-executed treatment [that] is worthwhile reading – both for those interested in competition law enforcement in pharmaceuticals, as well as those interested in any sector where dynamic considerations play a major role in defining the parameters of competition. […] Desogus’ rigorous and comprehensive approach is impressive and refreshing; it constitutes a valuable step forward by offering a skillful analysis of the relevant issues and a sophisticated analytical framework for examining dynamic efficiencies.’
Lauren Battaglia in 2011 CML Rev. 1374
‘ The book provides an important insight into the pharmaceutical industry and its complex structure, which causes concern among competition lawyers and advocates of the protection of innovation. […] the book bestows the reader with a good and well-guided insight into the pharmaceutical industry and its complexities as well as an interesting assessment of innovation in relation to competition law and parallel trade. […]Desogus has managed to explain and assess this in a simple, but non-patronising language that allows non-economists (i.e. read: figures-shy lawyers) to understand and follow her line of arguments without complications.’
Hedvig Schmidt in (2012) 37 E.L. Rev.358
About the author
Claudia Desogus is a lawyer and works in Italy in the fields of competition law and arbitration. She is also a Post-doc researcher at the University of Bologna and currently collaborates with Centre for European Policy Studies (CEPS) in Brussels. Dr. Desogus’ background combines both law and economics. She has a BA in Law (Bocconi University of Milan), a LL.M. in Law and Economics (University of Hamburg) and a Ph.D. in Law and Economics (University of Bologna and Erasmus University of Rotterdam). Previously, she worked in Brussels as a legal consultant on competition issues. Dr. Desogus has published in leading European and Italian law journals (ECLR, Giurisprudenza Commerciale, Il Diritto Industriale, etc.).
Introduction (p. 1)
Chapter I. The European Pharmaceutical Market (p. 11)
Chapter II. The Intersection between Intellectual Property Rights and Competition Policy Goals in the Pharmaceutical Sector (p. 79)
Chapter III. Competition and Regulation in the Pharmaceutical Market: The Case of Parallel Trade (p. 143)
Chapter IV. Parallel Trade and Pharmaceutical Innovation: The Emergence of the ‘Efficiency Defence’ in European Competition Law (p. 205)
Chapter V. The Welfare Effect of Parallel Trade: A Workable Rule of Reason (p. 259)
Conclusions and Future Research (p. 307)
List of References (p. 311)
Parts of this book have been made open access. We make chapters open access because they are particularly topical, or provide a useful introduction to the subject. They may be available for a limited time or indefinitely. Some books are entirely and permanently open access.
The series European Studies in Law and Economics is devoted to further the understanding of Law and Economics in Europe. The volumes published in this series present an interdisciplinary perspective on the effects of laws on people’s behaviour and on the economic system. The ample topics address a wide audience, including policy makers, legislators, economists, lawyers and judges. The series is peer-reviewed.
The series is an initiative of the PhD programme ‘European Doctorate in Law and Economics’ (EDLE). The EDLE is the academic response to the increasing importance of the economic analysis of law in Europe. The programme is offered by the Universities of Bologna, Hamburg and Rotterdam in association with the Indira Gandhi Institute of Development Research, Mumbai (India). PhD students receive the unique opportunity to study law and economics in three different countries. The programme prepares economists and lawyers of high promise for an academic career in a research field of growing importance or for responsible positions in government, research organisations and international consulting firms.
The European Commission sponsors the EDLE as an excellence programme under the prestigious Erasmus Mundus scheme. For further information please visit: www.edle-phd.eu.
The editorial board of the series consists of Prof. Dr. Michael G. Faure (Erasmus University Rotterdam), Prof. Dr. Luigi A. Franzoni (University of Bologna) and Prof. Dr. Stefan Voigt (University of Hamburg).
With a subscription to the series you enjoy a 15% discount on each volume!